Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of GoodwillAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harvard Bioscience (HBIO) Gains from Investment Securities (2017 - 2025)

Historic Gains from Investment Securities for Harvard Bioscience (HBIO) over the last 12 years, with Q3 2025 value amounting to $660755.0.

  • Harvard Bioscience's Gains from Investment Securities fell 2548.28% to $660755.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $660755.0, marking a year-over-year decrease of 2548.28%. This contributed to the annual value of $827458.0 for FY2024, which is 1045.48% down from last year.
  • Harvard Bioscience's Gains from Investment Securities amounted to $660755.0 in Q3 2025, which was down 2548.28% from $708793.0 recorded in Q2 2025.
  • Harvard Bioscience's 5-year Gains from Investment Securities high stood at $2.1 million for Q4 2023, and its period low was $47000.0 during Q1 2024.
  • Moreover, its 5-year median value for Gains from Investment Securities was $924858.0 (2023), whereas its average is $1.0 million.
  • In the last 5 years, Harvard Bioscience's Gains from Investment Securities skyrocketed by 104374.14% in 2021 and then plummeted by 8878.27% in 2023.
  • Over the past 5 years, Harvard Bioscience's Gains from Investment Securities (Quarter) stood at $861000.0 in 2021, then surged by 49.58% to $1.3 million in 2022, then skyrocketed by 60.88% to $2.1 million in 2023, then crashed by 38.32% to $1.3 million in 2024, then plummeted by 48.3% to $660755.0 in 2025.
  • Its Gains from Investment Securities was $660755.0 in Q3 2025, compared to $708793.0 in Q2 2025 and $75000.0 in Q1 2025.